A Phase 4 interventional study of Duration of antibiotics in Infections, Urinary Tract and Nephrolithiasis, sponsored by University of California, San Francisco. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment
Principal investigator and other key study team members departed the original institution and lack local support for study completion. Therefore, decision was made not to continue the study.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 161st largest by enrollment of the 225 interventional ones that give a count, is one of 17 that started in 2024, is one of 40 in phase 4, and was the 223rd registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Megan Bradley · Sites in United States
Ages 65+ · Women only
Baylor College of Medicine · Sites in United States
Ages 0 mo–5 mo · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
275 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 40
First in 1988; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 100 across the 225 interventional studies, 229 across the 50 observational. Of the 190 that completed or were terminated, 89 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 275 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 6 studies filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
26 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT07947108Good Kitty CoA Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms | 2026-12 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 275 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this non-inferiority randomized controlled trial: is to test the hypothesis that the that there is no additional benefit from a longer course (7 days) versus a shorter course (2 days) of pre-operative antibiotics in patients with moderate to high risk of infection undergoing ureteroscopy. The main questions it aims to answer are:
Post-operative infectious complications including urinary tract infection (UTI), systemic inflammatory response syndrome (SIRS), and sepsis are uncommon but potentially devastating complications after ureteroscopy. The clinical guidance from the American Urologic Association (AUA) and the European Association of Urology (EAU) is to provide treatment for symptomatic urinary tract infections however the management for asymptomatic patients with positive cultures or those patients who are otherwise at high risk of urinary tract colonization is unclear. As a result, there is significant practice variation in pre-operative prophylactic antibiotic prescription, even amongst fellowship trained endourologists, with some providers prescribing over ten days of pre-operative antibiotics while others offer none. This is a critical gap in our understanding of pre-operative prophylactic antibiotic utilization in a population of patients not only at higher risk of harboring multi-drug resistant (MDR) organisms but are also more susceptible to deleterious outcomes due to their frailty. Recent randomized trials have demonstrated that short courses of pre-operative antibiotics are no less protective than long courses in patients undergoing percutaneous nephrolithotomy (PCNL) for stone removal. Ureteroscopy is the most commonly performed stone surgery worldwide. Establishing an evidence-based approach for antibiotic prophylaxis in the ureteroscopic surgical patient population will be impactful for a large number of patients. The goal of this study is to implement a well-designed randomized clinical trial to establish the standardized antibiotic protocol necessary to minimize unnecessary antibiotic use which may otherwise lead to adverse reactions and proliferation of multi-drug resistant organisms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Duration of antibiotics
Drug: Duration of antibiotics
Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
Infectious Complication Rate
any occurrence of urinary tract infection, pyelonephritis, systemic inflammatory response syndrome or sepsis
Time frame: 30 days after surgery
Non-infectious Complications Including Readmission
Any other complications after the surgical procedure such as pain, readmission, urinary retention, etc
Time frame: 30 days after surgery
Adverse Reaction to Antibiotic Regimen
Any adverse reaction to antibiotic regimen
Time frame: 2-7 days prior to surgery (depending on which arm the patient was randomized to)
| Milestone | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) |
|---|---|---|
| Started | 18 | 16 |
| Completed | 18 | 16 |
| Not completed | 0 | 0 |
any occurrence of urinary tract infection, pyelonephritis, systemic inflammatory response syndrome or sepsis
| Participants | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) |
|---|---|---|
| Infectious complication occurence | 1 | 1 |
| infectious complication did not occur | 17 | 15 |
Any other complications after the surgical procedure such as pain, readmission, urinary retention, etc
| Participants | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) |
|---|---|---|
| Non-infectious complication did occur | 5 | 3 |
| Non-infectious complication did not occur | 13 | 13 |
Any adverse reaction to antibiotic regimen
| Participants | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) |
|---|---|---|
| Adverse reaction to antibiotic occurred | 0 | 0 |
| Adverse reaction to antibiotic did not occur | 18 | 16 |
Collected over From enrollment until end of follow up, up to 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Short Duration of Preoperative Antibiotics (2 Days) | 0/18 (0%) | 1/18 (5.6%) | 5/18 (27.8%) |
| Long Duration of Preoperative Antibiotics (7 Days) | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Event | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) |
|---|---|---|
| Postoperative sepsis requiring ICU admissionRenal and urinary disorders | 1/18 | 0/16 |
| Event | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) |
|---|---|---|
| Postoperative pain or lower urinary tract symptoms requiring evaluation in emergency departmentInjury, poisoning and procedural complications | 5/18 | 3/16 |
| Urinary tract infectionRenal and urinary disorders | 0/18 | 1/16 |
| Age, Continuous(years) | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) | Total |
|---|---|---|---|
| Median | 61 (47 to 65) | 60 (46 to 68) | 60 (46 to 68) |
| Sex: Female, Male(Participants) | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) | Total |
|---|---|---|---|
| Female | 7 | 10 | 17 |
| Male | 11 | 6 | 17 |
| Race (NIH/OMB)(Participants) | Short Duration of Preoperative Antibiotics (2 Days) | Long Duration of Preoperative Antibiotics (7 Days) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 11 | 12 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We have no plans to make individual participant data available to other researchers.
Ran from Jan 2024 to primary completion in Jul 2025, 18 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2026 → Jul 2025 and completion Jan 2026 → Jul 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Principal investigator and other key study team members departed the original institution and lack local support for study completion. Therefore, decision was made not to continue the study.
Principal investigator and other key study team members departed the original institution and lack local support for study completion. Therefore, decision was made not to continue the study.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →